NO20024201L - Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase - Google Patents

Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase

Info

Publication number
NO20024201L
NO20024201L NO20024201A NO20024201A NO20024201L NO 20024201 L NO20024201 L NO 20024201L NO 20024201 A NO20024201 A NO 20024201A NO 20024201 A NO20024201 A NO 20024201A NO 20024201 L NO20024201 L NO 20024201L
Authority
NO
Norway
Prior art keywords
substituted
alkyl
cycloalkyl
aryl
oxdiazol
Prior art date
Application number
NO20024201A
Other languages
English (en)
Other versions
NO20024201D0 (no
NO323483B1 (no
Inventor
Karl Schoenafinger
Stefan Petry
Guenter Mueller
Karl-Heinz Baringhaus
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000110968 external-priority patent/DE10010968A1/de
Priority claimed from DE2001102265 external-priority patent/DE10102265C1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20024201D0 publication Critical patent/NO20024201D0/no
Publication of NO20024201L publication Critical patent/NO20024201L/no
Publication of NO323483B1 publication Critical patent/NO323483B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/1131,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Det er beskrevet substituerte 3-fenyl-5-alkoksy-l,3,4-oksdiazol-2-oner med formel (1). hvori Rbetyr CC-alkyl og C-Cy-sykloalkyl; R, R, Rog R5 betyr hydrogen, halogen, nitro, C-Q-alkyl, C|-C-alkyloksy, substituert C-C-aryl-CI-C4-alkyloksy, C-C-aryloksy, C-C-aryl, C-Cx-sykloalkyl eller O-CC-sykloalkyl eller 2-oksopyrrolidin-l-yl, 2,5-dimetylpyrrol-l-yl eller NRA-R, under den forutsetning at R, R, Rog Rikke samtidig betyr hydrogen og minst én av restene R2, R3, R4 eller Rstår for resten 2-oksopyrrolidin-l-yl, 2,5-dimetylpyrrol-l-yl eller NR(-A-R, med R6 = hydrogen, C-G-alkyl eller substituert C-C,-aryl-C,-C-aIkyl, A = enkeltbinding, COn, SOn eller CONH; n = 1 eller 2; R= hydrogen, substituert C,-C|-alkyl, C:-C,- alkenyl, Cf,-C„-aryl-CC-alkyl, C-Cx-sykloalkyl-C-C-alkyl, C-Cx-sykloalkyl, C-aryl-C-Ch-alkenyl, Cf,-C-aryl, difenyl, difenyl-C|-C-alkyl, indanyl, eller gruppen Het-(CH)-, med r = 0, 1,2 eller 3 og Het = mettet eller umettet 5-7-leddet heterosyklus, som kan være benzokondensert og substituert, samt en fremgangsmåte for fremstilling av forbindelsene. Forbindelsene viser en hemmende virkning på den hormonsensitive lipasen, HSL.
NO20024201A 2000-03-07 2002-09-03 Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase samt fremgangsmate for fremstilling av forbindelsene. NO323483B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2000110968 DE10010968A1 (de) 2000-03-07 2000-03-07 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE2001102265 DE10102265C1 (de) 2001-01-18 2001-01-18 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
PCT/EP2001/001898 WO2001066531A1 (de) 2000-03-07 2001-02-20 Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase

Publications (3)

Publication Number Publication Date
NO20024201D0 NO20024201D0 (no) 2002-09-03
NO20024201L true NO20024201L (no) 2002-09-03
NO323483B1 NO323483B1 (no) 2007-05-21

Family

ID=26004720

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024201A NO323483B1 (no) 2000-03-07 2002-09-03 Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase samt fremgangsmate for fremstilling av forbindelsene.

Country Status (28)

Country Link
US (1) US6369088B2 (no)
EP (1) EP1263745B1 (no)
JP (1) JP2003525931A (no)
KR (1) KR100790763B1 (no)
CN (1) CN1261419C (no)
AR (1) AR027611A1 (no)
AT (1) ATE267184T1 (no)
AU (1) AU784827B2 (no)
BR (1) BR0108974A (no)
CA (1) CA2401953A1 (no)
DE (1) DE50102325D1 (no)
DK (1) DK1263745T3 (no)
EE (1) EE04877B1 (no)
ES (1) ES2218383T3 (no)
HK (1) HK1054036B (no)
HR (1) HRP20020732A2 (no)
HU (1) HUP0302772A3 (no)
IL (1) IL151518A (no)
MX (1) MXPA02008038A (no)
NO (1) NO323483B1 (no)
NZ (1) NZ521207A (no)
PL (1) PL359702A1 (no)
PT (1) PT1263745E (no)
RU (1) RU2281283C2 (no)
SK (1) SK12752002A3 (no)
TR (1) TR200401217T4 (no)
WO (1) WO2001066531A1 (no)
YU (1) YU57802A (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
DE10208986A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
US6900233B2 (en) 2002-02-28 2005-05-31 Aventis Pharma Deutschland Gmbh Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof
DE10208987A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
US20090082435A1 (en) * 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
TW201033163A (en) * 2008-10-20 2010-09-16 Sumitomo Chemical Co Method for manufacturing oxadiazolinone compound and intermediate thereof
AR074978A1 (es) 2008-12-23 2011-03-02 Bial Portela & Ca Sa 3-n-aril-1,3,4-oxadiazolonas 5-o-sustituidas para uso en el tratamiento del dolor y procedimiento de obtencion
WO2011108724A1 (ja) 2010-03-04 2011-09-09 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
EP2713722B1 (en) * 2011-05-31 2017-03-15 Receptos, LLC Novel glp-1 receptor stabilizers and modulators
ES2836973T3 (es) 2011-12-12 2021-06-28 Receptos Llc Derivados de ácido carboxílico que comprenden cuatro ciclos que actúan como moduladores de receptor GLP-1 para la terapia de enfermedades tales como la diabetes
BR112015031040A8 (pt) 2013-06-11 2018-01-02 Receptos Inc Novos moduladores do receptor de glp-1
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
US9474755B2 (en) 2014-07-25 2016-10-25 Celgene International Ii Sarl GLP-1 receptor modulators
CA2969944A1 (en) 2014-12-10 2016-06-16 Celgene International Ii Sarl Glp-1 receptor modulators
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN108863774A (zh) * 2018-06-09 2018-11-23 石家庄市绿丰化工有限公司 一种2,4-二氯苯乙酰氯合成的方法
KR20210102887A (ko) 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076824A (en) 1975-02-03 1978-02-28 Rhone-Poulenc Industries Anthelmintic oxadiazolinone derivatives
FR2299028A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Nouvea
FR2299328A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Derives de l'alcoyloxy-5 phenyl-3 oxyde azo
DK156439C (da) 1980-09-15 1990-01-22 Shell Int Research 7-substituerede 2,3-dihydrobenzofuranderivater samt pesticidpraeparater indeholdende disse og en fremgangsmaade til bekaempelse af skadelige organismer
EP0067471B1 (en) 1981-06-15 1985-11-06 Shell Internationale Researchmaatschappij B.V. 7-substituted 2,3-dihydrobenzofurans, their preparation and their use as pesticides or as chemical intermediates
DE3931843A1 (de) 1989-09-23 1991-04-04 Bayer Ag Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten
US5236939A (en) 1989-09-23 1993-08-17 Bayer Aktiengesellschaft Substituted 1,3,4-oxa(thia)diazolinones process for their preparation and their use of combating endoparasites
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents

Also Published As

Publication number Publication date
RU2281283C2 (ru) 2006-08-10
DE50102325D1 (de) 2004-06-24
CN1261419C (zh) 2006-06-28
HK1054036A1 (en) 2003-11-14
IL151518A0 (en) 2003-04-10
WO2001066531A1 (de) 2001-09-13
TR200401217T4 (tr) 2004-06-21
HUP0302772A3 (en) 2007-03-28
ATE267184T1 (de) 2004-06-15
US6369088B2 (en) 2002-04-09
US20010031772A1 (en) 2001-10-18
CN1416424A (zh) 2003-05-07
PL359702A1 (en) 2004-09-06
EE200200498A (et) 2004-02-16
NO20024201D0 (no) 2002-09-03
HK1054036B (zh) 2006-11-17
DK1263745T3 (da) 2004-08-16
CA2401953A1 (en) 2001-09-13
JP2003525931A (ja) 2003-09-02
HRP20020732A2 (en) 2004-12-31
AU784827B2 (en) 2006-06-29
MXPA02008038A (es) 2004-04-05
KR20020079986A (ko) 2002-10-21
IL151518A (en) 2008-06-05
PT1263745E (pt) 2004-09-30
NO323483B1 (no) 2007-05-21
SK12752002A3 (sk) 2003-04-01
AU3378701A (en) 2001-09-17
HUP0302772A2 (hu) 2003-11-28
WO2001066531A8 (de) 2002-07-25
KR100790763B1 (ko) 2008-01-03
EP1263745A1 (de) 2002-12-11
BR0108974A (pt) 2003-06-03
YU57802A (sh) 2005-07-19
NZ521207A (en) 2005-04-29
AR027611A1 (es) 2003-04-02
EE04877B1 (et) 2007-08-15
EP1263745B1 (de) 2004-05-19
ES2218383T3 (es) 2004-11-16

Similar Documents

Publication Publication Date Title
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
NO20006282L (no) Nye cyklosporiner
HUP0204418A2 (hu) NHE-1 inhibitor hatású N-[(helyettesített öttagú, di- vagy triaza-, kétszeresen telítetlen gyűrű)-karbonil]-guanidin-származékok és alkalmazásuk
NO971471L (no) Nye karboksamider med fungicid aktivitet
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
NO954453L (no) Nye pyridin-, pyrimidin- og benzenderivater som adreno-ceptorantagonister
NO924522L (no) Optisk aktive azolforbindelser, deres fremstilling og anvendelse
MY108831A (en) N-(4-piperidinyl) (dihydrobenzofuran of dihydro-2h- benzopyran) carboxamide derivatives.
WO2001066531A8 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase
NO913923L (no) 17beta-substituerte-4-aza-5alfa-androstan-3-on-derivater ogfremgangsmaate ved fremstilling av disse
NO996108L (no) 9-oksinerytromycinderivater
PT1278728E (pt) Derivados de pirrolidina e de piperidina e sua utilizacao no tratamento de disturbios neurodegenerativos
MY132473A (en) Crystalline hydrochloride of (r)-(-)-2-<n-[4-(1,1- dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl>-chroman
ES8401959A1 (es) Un procedimiento para la produccion de un derivado de carbostirilo.
GR3006247T3 (no)
CA2206005A1 (en) Aniline derivatives possessing an inhibitory effect of nitric oxide synthase
NO970293L (no) Substituerte camptothecinderivater og fremgangsmåte for deres fremstilling
NO20015172L (no) 1-metyl-erytromycin-derivater
DE69229339D1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
NO20000722L (no) 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
ATE128463T1 (de) Piperidin und pyrrolidin derivate.
MY129663A (en) Antihistaminic spiro compounds
NO932130L (no) Hemmere av HIV-protease som er nyttige for behandling av AIDS
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII